t:slim X2, meanwhile, is powered by Control-IQ+ technology. Tandem designed the advanced hybrid closed-loop automated insulin delivery feature to predict and help prevent high and low blood sugar.

GR-He-LSE-2.png Jun 28, 2025 Bobby Jenks, 2-time All-Star closer and World Series champion with the Chicago White Sox, dies at 44 ...

Abbott’s ABT diversified business portfolio appears to be well-positioned to drive continued momentum in 2025. The stock carries a Zacks Rank #2 (Buy) currently. Within Abbott’s Established ...

Key collaborations enable Abbott to increase its global presence and accessibility to patients who haven't used CGMs before.

Abbott Sees Upside on Diagnostics Growth, FreeStyle Libre Expansion July 02, 2025 — 10:01 am EDT Written by Zacks Equity Research for Zacks -> ...

Cencora, carrying a Zacks Rank #2 at present, has an earnings yield of 5.4% compared with the industry’s 3.8%. Shares of the company have rallied 25.9% against the industry’s 14.4% decline.

SAN DIEGO, June 20, 2025--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company today announced the Tandem t:slim X2™ insulin pump with Control-IQ+ ...

The latest version of Abbott's FreeStyle Libre continuous glucose monitor is now available via the NHS to eligible people with diabetes in the UK. Abbott's wearable FreeStyle Libre 3 device ...

Tandem Diabetes Care Announces t:slim X2™ Insulin Pump Compatibility with Abbott’s FreeStyle Libre® 3 Plus Sensor in the United States Business Wire Jun 20, 2025 ...

Abbott’s ABT diversified business portfolio appears to be well-positioned to drive continued momentum in 2025. The stock carries a Zacks Rank #2 (Buy) currently. Factors Driving ABT Shares Within ...